Moreover, immune dysregulation in IBD patients involves various interleukins, such as IL-6, IL-12, IL-17, and TNF-α, which not only exacerbate intestinal inflammation but affect mood and behaviour through their systemic effects. Here, IL17A is linked to irritable bowel syndrome.